High-dose proton therapy and tomotherapy for the treatment of sacral chordoma: a retrospective monocentric study

References

• Bakker SH, Jacobs WCH, Pondaag W, et al. Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival. Eur Spine J. 2018;27(12):3043–3058.
   PubMed Web of Science ®Google Scholar
• Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer. 2012;131(4):E508–E517.
   PubMed Web of Science ®Google Scholar
• Varga PP, Szövérfi Z, Fisher CG, et al. Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival. Eur Spine J. 2015;24(5):1092–1101.
   PubMed Web of Science ®Google Scholar
• Kerekes D, Goodwin CR, Ahmed AK, et al. Local and distant recurrence in resected sacral chordomas: a systematic review and pooled cohort analysis. Glob. Spine J. 2019;9(2):191–201.
   PubMed Web of Science ®Google Scholar
• Colangeli S, Muratori F, Bettini L, et al. Surgical treatment of sacral chordoma: en bloc resection with negative margins is a determinant of the long-term outcome. Surg Technol Int 2018;33:343–348.
   PubMedGoogle Scholar
• Rotondo RL, Folkert W, Liebsch NJ, et al. High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors. J. Neurosurg Spine. 2015;23(6):788–797.
   PubMed Web of Science ®Google Scholar
• Dial BL, Kerr DL, Lazarides AL, et al. The Role of Radiotherapy for Chordoma Patients Managed with Surgery: analysis of the national cancer database. Spine. 2020;45:E742–E751.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Sommer J. Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16(2):e71–83–e83.
   PubMed Web of Science ®Google Scholar
• Pennicooke B, Laufer I, Sahgal A, et al. Safety and local control of radiation therapy for chordoma of the spine and sacrum: a systematic review. Spine. 2016;41:S186–S192.
   PubMed Web of Science ®Google Scholar
• Bjornsson J, Wold LE, Ebersold MJ, et al. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer. 1993;71(3):735–740.
   PubMed Web of Science ®Google Scholar
• Park L, DeLaney TF, Liebsch NJ, et al. Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int. J. Radiat. Oncol. 2006;65(5):1514–1521.
   PubMed Web of Science ®Google Scholar
• DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014;110(2):115–122.
   PubMed Web of Science ®Google Scholar
• Kabolizadeh P, Chen Y-L, Liebsch N, et al. Updated Outcome and Analysis of Tumor Response in Mobile Spine and Sacral Chordoma Treated With Definitive High-Dose Photon/Proton Radiation Therapy. Int J Radiat Oncol. 2017;97(2):254–262.
   PubMed Web of Science ®Google Scholar
• Youn SH, Cho KH, Kim J-Y, et al. Clinical outcome of proton therapy for patients with chordomas. Radiat Oncol J. 2018;36(3):182–191.
   PubMed Web of Science ®Google Scholar
• Aibe N, Demizu Y, Sulaiman NS, et al. Outcomes of patients with primary sacral chordoma treated with definitive proton beam therapy. Int J Radiat Oncol Biol Phys. 2018;100(4):972–979.
   PubMed Web of Science ®Google Scholar
• R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. Available from: http://www.R-project.org
   Google Scholar
• Yin P, Mao N, Zhao C, et al. Comparison of radiomics machine-learning classifiers and feature selection for differentiation of sacral chordoma and sacral giant cell tumour based on 3D computed tomography features. Eur Radiol. 2019;29(4):1841–1847.
   PubMed Web of Science ®Google Scholar
• Yin P, Mao N, Zhao C, et al. A Triple-Classification Radiomics Model for the Differentiation of Primary Chordoma, Giant Cell Tumor, and Metastatic Tumor of Sacrum Based on T2-Weighted and Contrast-Enhanced T1-Weighted MRI. J Magn Reson Imaging. 2019;49(3):752–759.
   PubMed Web of Science ®Google Scholar
• Yin P, Mao N, Wang S, et al. Clinical-radiomics nomograms for pre-operative differentiation of sacral chordoma and sacral giant cell tumor based on 3D computed tomography and multiparametric magnetic resonance imaging. BJR. 2019;92(1101):20190155.
   Google Scholar
• Chen Y-L, Liebsch N, Kobayashi W, et al. Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. Spine. 2013;38(15):E930–E936.
   PubMed Web of Science ®Google Scholar
• Zabel-Du Bois A, Nikoghosyan A, Schwahofer A, et al. Intensity modulated radiotherapy in the management of sacral chordoma in primary versus recurrent disease. Radiother Oncol. 2010;97(3):408–412.
   PubMed Web of Science ®Google Scholar
• Bobin M, Zacharatou C, Sargos P, et al. Helical tomotherapy of spinal chordomas: French Multicentric, retrospective study of a cohort of 30 cases. Radiat Oncol. 2017;12(1):32.
   PubMedGoogle Scholar
• Schneider C, Vyfhuis M, Morse E, et al. Dramatic response of a large sacral chordoma to intensity modulated proton beam therapy. Cureus. 2017;9(9):e1670.
   PubMed Web of Science ®Google Scholar